Joined as a new investor in Parabilis Medicines' oversubscribed $305M Series F financing.
JAN 8, 2026
Participated as an existing investor in Parabilis Medicines' oversubscribed $305M Series F to advance zolucatetide toward Phase 3.
JAN 8, 2026
Parabilis is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable
Parabilis is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable.